SF's "sexmaxxing" trend has a venture layer: Feel Peptides raised $3M led by Brian Sugar's Sugar Capital. No Form D confirms the round, the product is off-label, and an independent lab says 43 of 114 PT-141 samples failed purity checks.

The San Francisco Standard's Friday dispatch from the city's "sexmaxxing" scene — techies injecting the peptide PT-141 before date night — buries the part that matters to anyone tracking the money: there is now venture capital behind the needles. Feel Peptides, a gray-market seller of oxytocin, PT-141, and kisspeptin, raised $3 million in a round led by Brian Sugar's Sugar Capital, per the Standard. Sugar, the PopSugar co-founder turned investor, is quoted on the record: "Rather than trying a different gin or vodka, it's more interesting to try different peptides in your body. … The next 25 years are going to be absolutely bonkers."

Here is the cap-table reality. A search of SEC EDGAR turns up no Form D for Feel Peptides under that or nearby entity names — so the $3 million figure rests on the Standard's reporting and the company's word, not a filing you can pull. The product itself is unapproved for the use being sold: PT-141 (bremelanotide) reached market in 2019 as Vyleesi, cleared by the FDA only for premenopausal women with hypoactive sexual desire disorder. Everything else — men, postmenopausal women, "sextides" traded at $30 a vial at tasting parties — is off-label.

And the supply is dirty. Finnrick, a peptide-testing platform, told the Standard it screened 114 PT-141 samples over the past year; 43 failed, either under 99.5% purity or mislabeled. That is a 38% failure rate in a product now attracting institutional money.

This is the same trade I flagged in July, when Superpower — another SF peptide startup — was carrying a $432 million valuation on $47 million raised amid an unsettled FDA posture. The demand is real: Reve Health Institute reports a 25–30% jump in "sexmaxxing" patients. What's unconfirmed is whether Feel's raise ever gets papered, and whether "bonkers" survives the first quality-control lawsuit.